Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
| Status: | Recruiting |
|---|---|
| Conditions: | Lymphoma, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 12/14/2018 |
| Start Date: | November 30, 2017 |
| End Date: | April 2020 |
| Contact: | TG Therapeutics Clinical Support Team |
| Email: | clinicalsupport@tgtxinc.com |
| Phone: | 212-554-4279 |
A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
This research study will evaluate the safety and efficacy of a study drug called Umbralisib
(also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia
and Marginal Zone Lymphoma that has come back or that has not responded to standard
treatment.
(also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia
and Marginal Zone Lymphoma that has come back or that has not responded to standard
treatment.
Inclusion Criteria:
- Confirmed diagnosis of Marginal Zone Lymphoma or Waldenstroms Macroglobulinemia
- Relapsed or refractory after at least one prior treatment regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
- Prior autologous stem cell transplant within 6 months of study entry
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials